Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen Therapeutics, Inc. jointly announced that the...
Orexigen Therapeutics announced it has entered into an agreement with Takeda to acquire the United States rights to Contrave (naltrexone...
Takeda Pharmaceutical Company Limited and Orexigen Therapeutics, Inc. have accepted the recommendation of the Executive Steering Committee (ESC), chaired by...
Orexigen has submitted the Marketing Authorization Application for Contrave (naltrexone HCl/bupropion) to the European Medicines Agency. It is seeking approval...
Orexigen Therapeutics has resubmitted the Contrave (naltrexone sustained release (SR)/bupropion SR) New Drug Application to the FDA for weight loss...
Orexigen Therapeutics has announced that results of its IGNITE study of Contrave (bupropion and naltrexone) in obesity were published online...
Orexigen Therapeutics announced that Valeant Pharmaceuticals will commercialise Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern...
Take a look at a series of drug options and their effectiveness as treatments for obesity, as well as their ability to tackle diabetes and cardiovascular disease.